Effect on High Density Lipoprotein Cholesterol of Atenolol and Oxprenolol in Patients with Mild Essential Hypertension

1982 ◽  
Vol 63 (s8) ◽  
pp. 463s-465s ◽  
Author(s):  
S. E. Kjeldsen ◽  
I. Eide ◽  
P. Leren ◽  
O. P. Foss
Keyword(s):  
Essential Hypertension ◽  
High Density Lipoprotein ◽  
Blood Pressure Reduction ◽  
Density Lipoprotein ◽  
Clinical Importance ◽  
Hdl Cholesterol ◽  
High Density ◽  
Cholesterol Ratio ◽  
Group I ◽  
Effect Of Treatment

1. Nineteen healthy men aged 50 years, with untreated, mild essential hypertension WHO group I, were randomized into two groups to study the effect of treatment (18 weeks) with oxprenolol (n = 10) and atenolol (n = 9) on serum cholesterol fractions, total triglycerides and uric acid. 2. Oxprenolol lowered high density lipoprotein (HDL) cholesterol by 11.4% (P < 0.02) and cholesterol ratio (HDL cholesterol × 100/LDL + VLDL cholesterol) by 13.7% (P < 0.05). Atenolol lowered HDL cholesterol by 16.5% (P < 0.02) and cholesterol ratio by 19.2% (P < 0.01). 3. Oxprenolol and atenolol raised total triglycerides by 20.0% and 17.9% respectively. Only with atenolol was this increment statistically significant (P < 0.05). 4. The HDL cholesterol lowering effect of oxprenolol and atenolol observed in the present study may have clinical importance, since such metabolic side effects have been postulated to counteract the beneficial effect of blood pressure reduction on development of atherosclerosis and coronary heart disease in mild essential hypertension.

scholarly journals Is There Any Association Between Uric Acid to High-density Lipoprotein Cholesterol Ratio and Erectile Dysfunction?

2021 ◽  
Author(s):  
Dilay Karabulut ◽  
Mustafa Gürkan Yenice
Keyword(s):  
Uric Acid ◽  
Erectile Dysfunction ◽  
High Density Lipoprotein ◽  
Roc Curve ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
High Density ◽  
Roc Curve Analysis ◽  
Cholesterol Ratio ◽  
Group 3

Objective: Elevated uric acid (UA) and low levels of high-density lipoprotein (HDL) cholesterol are associated with cardiovascular events and mortality. Erectile dysfunction (ED) has been considered an early marker of cardiovascular disease (CVD). Therefore, this study aimed to investigate the uric acid/ HDL ratio (UHR) as a nowel marker in patients with ED. Materials and Methods: The study included 147 patients with a mean age of 50 years (range 32-76 years). Retrospective analyses were performed on the patients who were admitted to urology outpatient clinics. The laboratory parameter results were retrieved from the hospital medical records, and the UHR value was calculated. Patients were categorized into three groups according to the International Index of Erectile Function (IIEF) score. UHR was compared between groups, and its predictive value was evaluated using regression analysis and ROC curve analysis. Results: Age was found to be significantly different in all three groups (Groups 1-2, p=0.001; Groups 1-3, p=0.000; Groups 2-3, p=0.001). It was observed that the degree of ED increased with age. The values of UA and HDL were similar in all groups (p>0.05). In contrast, the UHR value was statistically significantly higher 0.15 (0.083-0.288, p =0.047) in the moderate-severe ED (Group 3). ROC curve analyses revealed that UHR predicted severe ED (IIEF 5-11) with 42.9% sensitivity and 87.3% specificity (AUC:0.66, CI 95% 0.538-0.781, p=0.019). Conclusion: UHR may serve as a severe ED indicator in patients admitted to the cardiology outpatient clinic since it has a significant association with a low IIEF score.

Effects of Smoking on Oral Fat Tolerance and High Density Lipoprotein Cholesterol

1983 ◽  
Vol 65 (6) ◽  
pp. 669-672 ◽  
Author(s):  
R. S. Elkeles ◽  
S. R. Khan ◽  
V. Chowdhury ◽  
M. B. Swallow
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
Serum Triglyceride ◽  
Hdl Cholesterol ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Fatty Meal ◽  
Cholesterol Ratio ◽  
Average Serum

1. Changes in serum triglyceride and high density lipoprotein (HDL) cholesterol after a fatty meal have been studied in smokers and non-smokers. 2. Average serum triglyceride during the study was higher in smokers than in non-smokers. 3. In non-smokers there was a rise in the HDL2/HDL3 cholesterol ratio after oral fat, but not in smokers. 4. These findings are compatible with the hypothesis that smoking interferes with the lipolysis of triglyceride rich lipoproteins and the conversion of HDL3 into HDL2.

scholarly journals Increased Oxidized High-Density Lipoprotein/High-Density Lipoprotein–Cholesterol Ratio as a Potential Indicator of Disturbed Metabolic Health in Overweight and Obese Individuals

2019 ◽  
Vol 51 (1) ◽  
pp. 24-33
Author(s):  
Jelena M Janac ◽  
Aleksandra Zeljkovic ◽  
Zorana D Jelic-Ivanovic ◽  
Vesna S Dimitrijevic-Sreckovic ◽  
Jelena Vekic ◽  
...  
Keyword(s):  
High Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Metabolic Health ◽  
High Density ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cholesterol Ratio ◽  
Amyloid A ◽  
Potential Indicator ◽  
Metabolically Healthy

AbstractBackgroundWe evaluated the qualitative characteristics of high-density lipoprotein (HDL) particles in metabolically healthy and unhealthy overweight and obese subjects.MethodsThe study involved 115 subject individuals classified as metabolically healthy and unhealthy, as in overweight and obese groups. Commercial enzyme-linked immunosorbent assay (ELISA) kits were used to measure oxidized HDL (OxHDL) and serum amyloid A (SAA) concentrations. Lipoprotein subfractions were separated using nondenaturing gradient gel electrophoresis.ResultsAn independent association was shown between increased OxHDL/HDL-cholesterol ratio and the occurrence of metabolically unhealthy phenotype in the overweight and obese groups. The OxHDL/HDL-cholesterol ratio showed excellent and acceptable diagnostic accuracy in determination of metabolic health phenotypes (overweight group, AUC = 0.881; obese group, AUC = 0.765). Accumulation of smaller HDL particles in metabolically unhealthy subjects was verified by lipoprotein subfraction analysis. SAA concentrations did not differ significantly between phenotypes.ConclusionsIncreased OxHDL/HDL-cholesterol ratio may be a potential indicator of disturbed metabolic health in overweight and obese individuals.

scholarly journals Higher High Density Lipoprotein 2 (HDL2) to Total HDL Cholesterol Ratio Is Associated with a Lower Risk for Incident Hypertension

2019 ◽  
Vol 43 (1) ◽  
pp. 114 ◽  
Author(s):  
You-Cheol Hwang ◽  
Wilfred Y. Fujimoto ◽  
Steven E. Kahn ◽  
Donna L. Leonetti ◽  
Edward J. Boyko
Keyword(s):  
High Density Lipoprotein ◽  
Lower Risk ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
High Density ◽  
Incident Hypertension ◽  
Cholesterol Ratio

scholarly journals Evaluation of lipogenic property of Phragmanthera capitata in diabetic rats

2016 ◽  
Vol 4 (6) ◽  
pp. 299-302
Author(s):  
Lapah Pièrre Takem ◽  
◽  
Augustine Dick Essien ◽  
Pius Monday Udia ◽  
Emmanuel Ikechi Anele ◽  
...  
Keyword(s):  
Blood Glucose ◽  
High Density Lipoprotein ◽  
Aqueous Extract ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Diabetic Rats ◽  
High Density ◽  
Cholesterol Levels ◽  
Group I ◽  
Wide Range

Objective: Phragmanthera capitata is a parasitic plant employed in the treatment of wide range of disorders in Cameroon folkloric medicine. The present study was carried out to evaluate lipogenic property of aqueous extract of the whole plant in alloxan-induced diabetic Wistar rats. Materials and Methods: Diabetic rats were grouped and treated as follows: Group I (control) received 10 ml/kg saline, Group II (standard) received 600 µg/kg glibenclamide and Groups III-V (tests) received 200, 400 and 800 mg/kg aqueous extract of P. capitata (AEPC) respectively for 15 days. Body weights of animals were recorded and blood glucose levels were assessed from tail prick in the course of the experiment. At the end of the experimental period, the animals were sacrificed and blood was collected via cardiac puncture for lipid profiling. Results: Body weight revealed a significant (P ≤0.05) increase except for the group treated with 400 mg/kg extract as compared to control group. Treatment with extract did not result in any significant change (P ≥0.05) in blood glucose level at all extract concentrations. However, the extract at 200 mg/kg significantly (P ≤0.05) reduced total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), non-high density lipoprotein (non-HDL) cholesterol levels, LDL/HDL ratio and significantly increased high density lipoprotein (HDL) cholesterol levels. Conclusion: Considering that lipogenesis encompasses both fatty acid and triglyceride synthesis, P. capitata aqueous extract at 200 mg/kg acted as anti-lipogenic agent. The extract also potentiated weight gain but exhibited non-significant (P ≥0.05) effect on blood glucose concentrations at the dose levels used.

The Effect of Insulin Delivery Route on Lipoproteins in Type I Diabetic Patients on CAPD

1999 ◽  
Vol 19 (2) ◽  
pp. 148-153 ◽  
Author(s):  
Pasi I. Nevalainen ◽  
Jorma T. Lahtela ◽  
Jukka Mustonen ◽  
Marja-Riitta Taskinen ◽  
Amos Pasternack
Keyword(s):  
Peritoneal Dialysis ◽  
Glycemic Control ◽  
High Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
High Density ◽  
Diabetic Patients ◽  
Type I ◽  
Subcutaneous Insulin ◽  
Cholesterol Ratio

Objective To evaluate the influence of subcutaneous and intraperitoneal (IP) insulin on plasma lipoproteins in type I diabetic (IDDM) patients with end-stage renal failure (ESRD) treated with continuous ambulatory peritoneal dialysis (CAPD). Design A before–after trial. Setting University hospital outpatient care. Participants Eleven IDDM patients with stabilized peritoneal dialysis, age 42.9 ± 2.9 (SEM) years and duration of diabetes 31.4 ± 3.4 years. Intervention Two treatment periods during stabilized CAPD. All patients were first treated with subcutaneous and then with IP insulin. The studies were performed after a median time of 3 months on each treatment. Main Outcome Measures Plasma lipids; apoproteins (Apo) A-I, A-II, and B; high-density lipoprotein (HDL) subfractions; glycemic status; and uremic status. Results After changing from subcutaneous insulin to IP insulin, plasma HDL cholesterol decreased (from 1.29 ± 0.13 mmol/L to 0.96 ± 0.06 mmol/L, p < 0.05), and the low density to high density lipoprotein (LDL/HDL) cholesterol ratio increased ( p < 0.05). The HDL cholesterol decreased in both HDL2 and HDL3 fractions, but significantly so only in HDL3 ( p < 0.01). ApoA-I ( p < 0.05) decreased while the ApoB/ApoA-I ratio ( p < 0.01) and the ApoA-I/HDL-cholesterol ratio ( p < 0.01) increased during IP insulin therapy. Intraperitoneal insulin resulted in significantly better glycemic control than subcutaneous insulin ( p < 0.01). Conclusions In diabetic patients on CAPD therapy, IP insulin, although inducing better glycemic control than subcutaneous insulin, was associated with lowered plasma HDL cholesterol and ApoA-I levels. The atherogenic potential is probably less than expected as the relative particle size of HDL remained unchanged.

Triglyceride to high density lipoprotein cholesterol ratio, total cholesterol to high density lipoprotein cholesterol ratio and low ankle brachial index in an elderly population

VASA ◽  
2014 ◽  
Vol 43 (3) ◽  
pp. 189-197 ◽  
Author(s):  
Yiqiang Zhan ◽  
Jinming Yu ◽  
Rongjing Ding ◽  
Yihong Sun ◽  
Dayi Hu
Keyword(s):  
High Density Lipoprotein ◽  
Total Cholesterol ◽  
High Density Lipoprotein Cholesterol ◽  
Ankle Brachial Index ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Cholesterol Ratio ◽  
Potential Biomarker

Background: The associations of triglyceride (TG) to high-density lipoprotein cholesterol ratio (HDL‑C) and total cholesterol (TC) to HDL‑C ratio and low ankle brachial index (ABI) were seldom investigated. Patients and methods: A population based cross-sectional survey was conducted and 2982 participants 60 years and over were recruited. TG, TC, HDL‑C, and low-density lipoprotein cholesterol (LDL-C) were assessed in all participants. Low ABI was defined as ABI ≤ 0.9 in either leg. Multiple logistic regression models were applied to study the association between TG/HDL‑C ratio, TC/HDL‑C ratio and low ABI. Results: The TG/HDL‑C ratios for those with ABI > 0.9 and ABI ≤ 0.9 were 1.28 ± 1.20 and 1.48 ± 1.13 (P < 0.0001), while the TC/HDL‑C ratios were 3.96 ± 1.09 and 4.32 ± 1.15 (P < 0.0001), respectively. After adjusting for age, gender, body mass index, obesity, current drinking, physical activity, hypertension, diabetes, lipid-lowering drugs, and cardiovascular disease history, the odds ratios (ORs) with 95 % confidence intervals (CIs) of low ABI for TG/HDL‑C ratio and TC/HDL‑C ratio were 1.10 (0.96, 1.26) and 1.34 (1.14, 1.59) in non-smokers. When TC was further adjusted, the ORs (95 % CIs) were 1.40 (0.79, 2.52) and 1.53 (1.21, 1.93) for TG/HDL‑C ratio and TC/HDL‑C ratio, respectively. Non-linear relationships were detected between TG/HDL‑C ratio and TC/HDL‑C ratio and low ABI in both smokers and non-smokers. Conclusions: TC/HDL‑C ratio was significantly associated with low ABI in non-smokers and the association was independent of TC, TG, HDL‑C, and LDL-C. TC/HDL‑C might be considered as a potential biomarker for early peripheral arterial disease screening.

scholarly journals High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 574
Author(s):  
Maria Pia Adorni ◽  
Nicoletta Ronda ◽  
Franco Bernini ◽  
Francesca Zimetti
Keyword(s):  
High Density Lipoprotein ◽  
Cholesterol Efflux ◽  
Current Knowledge ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
High Density ◽  
Current Evidence ◽  
Endocrine Disorders ◽  
Lifestyle Modifications ◽  
Cholesterol Efflux Capacity

Over the years, the relationship between high-density lipoprotein (HDL) and atherosclerosis, initially highlighted by the Framingham study, has been revealed to be extremely complex, due to the multiple HDL functions involved in atheroprotection. Among them, HDL cholesterol efflux capacity (CEC), the ability of HDL to promote cell cholesterol efflux from cells, has emerged as a better predictor of cardiovascular (CV) risk compared to merely plasma HDL-cholesterol (HDL-C) levels. HDL CEC is impaired in many genetic and pathological conditions associated to high CV risk such as dyslipidemia, chronic kidney disease, diabetes, inflammatory and autoimmune diseases, endocrine disorders, etc. The present review describes the current knowledge on HDL CEC modifications in these conditions, focusing on the most recent human studies and on genetic and pathophysiologic aspects. In addition, the most relevant strategies possibly modulating HDL CEC, including lifestyle modifications, as well as nutraceutical and pharmacological interventions, will be discussed. The objective of this review is to help understanding whether, from the current evidence, HDL CEC may be considered as a valid biomarker of CV risk and a potential pharmacological target for novel therapeutic approaches.

Sign in / Sign up

Export Citation Format

Share Document